The BRAF V600E mutation is found in approximately 6% of human cancers and mimics the phosphorylation of the kinase domain activation segment. In wild-type B-Raf (B-Raf wt ), activation segment phosphorylation is thought to cooperate with negative charges within the N-region for full activation. In contrast to Raf-1, the N-region of B-Raf is constitutively negatively charged owing to the presence of residues D447/D448 and the phosphorylation of S446. Therefore, it has been suggested that this hallmark predisposes B-Raf for oncogenic activation. In this study, we demonstrate that neutralizing mutations of these residues (in particular S446 and S447), or uncoupling of B-Raf from Ras-guanine 5 0 -triphosphate (GTP), strongly reduce the biological activity of B-Raf in a PC12 cell differentiation assay. We also confirm that S365 is a 14-3-3 binding site, and determine that mutation of this residue rescues the impaired biological activity of B-Raf proteins with a neutralized N-region, suggesting that the N-region opposes a 14-3-3-mediated transition into an inactive conformation. However, in the case of B-Raf V600E , although complete N-region neutralization resulted in a 2.5-fold reduction in kinase activity in vitro, this oncoprotein strongly induced PC12 differentiation or transformation and epithelial-mesenchymal transition of MCF-10A cells regardless of its N-region charge. Furthermore, the biological activity of B-Raf V600E was independent of its ability to bind Ras-GTP. Our analysis identifies important regulatory differences between B-Raf wt and B-Raf V600E and suggests that B-Raf V600E cannot be inhibited by strategies aimed at blocking S446 phosphorylation or Ras activation.
The BRAF V600E mutation is found in approximately 6% of human cancers and mimics the phosphorylation of the kinase domain activation segment. In wild-type B-Raf (B-Raf wt ), activation segment phosphorylation is thought to cooperate with negative charges within the N-region for full activation. In contrast to Raf-1, the N-region of B-Raf is constitutively negatively charged owing to the presence of residues D447/D448 and the phosphorylation of S446. Therefore, it has been suggested that this hallmark predisposes B-Raf for oncogenic activation. In this study, we demonstrate that neutralizing mutations of these residues (in particular S446 and S447), or uncoupling of B-Raf from Ras-guanine 5 0 -triphosphate (GTP), strongly reduce the biological activity of B-Raf in a PC12 cell differentiation assay. We also confirm that S365 is a 14-3-3 binding site, and determine that mutation of this residue rescues the impaired biological activity of B-Raf proteins with a neutralized N-region, suggesting that the N-region opposes a 14-3-3-mediated transition into an inactive conformation. However, in the case of B-Raf V600E , although complete N-region neutralization resulted in a 2.5-fold reduction in kinase activity in vitro, this oncoprotein strongly induced PC12 differentiation or transformation and epithelial-mesenchymal transition of MCF-10A cells regardless of its N-region charge. Furthermore, the biological activity of B-Raf V600E was independent of its ability to bind Ras-GTP. Our analysis identifies important regulatory differences between B-Raf wt and B-Raf V600E and suggests that B-Raf
Introduction
The Ras/Raf/mitogen-activated/extracellular-regulated kinase (MEK)/extracellular signal regulated kinase (ERK) pathway plays a pivotal role in control of proliferation and differentiation and, owing to its role as a gatekeeper of this pathway, Raf appears an attractive therapeutic target (O'Neill and Kolch, 2004; Wilhelm et al., 2004) . The Raf-kinase family comprises the A-Raf, B-Raf and Raf-1 isoforms in vertebrates as well as D-Raf and LIN-45 in Drosophila and Caenorhabditis, respectively. B-Raf, the major ERK activator in vertebrates, is required for the maintenance of basal ERK activity and displays the most potent transforming activity (Papin et al., 1998; Brummer et al., 2002; Mercer and Pritchard, 2003) . All isoforms share three highly conserved regions (CRs; Figure 1a ): the N-terminal CR1 contains the Ras-guanine 5 0 -triphosphate (GTP)-binding domain (RBD), which initiates the interaction with Ras-GTP through a conserved arginine residue (R188 in B-Raf) that is required for the recruitment and activation of Raf at the plasma membrane. Consequently, mutation of this residue prevents Ras/Raf interaction and renders D-Raf, B-Raf and Raf-1 unresponsive to most extracellular signals (Hou et al., 1995; Marais et al., 1997; Brummer et al., 2002) . The CR2 contains a negative regulatory serine residue (S259 and S365 in Raf-1 and B-Raf, respectively) that is proposed to serve as a binding site for 14-3-3 proteins, although this has only been confirmed for Raf-1 (Roy et al., 1998; Hekman et al., 2004) . The catalytic domain (CR3) harbours phosphorylation sites for Raf-regulating enzymes within two segments, the N-region and the activation segment (Mercer and Pritchard, 2003) . All isoforms carry a second 14-3-3 binding motif at the C-terminal end of the CR3 domain and its mutation abrogates the biological activity of B-Raf, Raf-1 and LIN-45, demonstrating also a conserved positive role of 14-3-3 proteins for the coupling of Raf to downstream effectors (MacNicol et al., 2000; Light et al., 2002; Harding et al., 2003) .
So far, most studies have focused on the activation of Raf-1 and the following model of Raf-1 activation has emerged: In unstimulated cells, Raf-1 is phosphorylated on S259 and S621 (S365 and S729 in B-Raf), which mediate its binding to a 14-3-3 protein dimer (Roy et al., 1998; Hekman et al., 2004) . This dimer is proposed to tether the regulatory and catalytic lobes together and thereby stabilize a closed, inactive conformation of Raf-1. Upon binding to Ras-GTP, 14-3-3 is displaced from phospho-S259 and its re-binding is prevented by S259 dephosphorylation (Dhillon et al., 2002) . This induces an open conformation leading to the exposure of the MEK docking site and the phosphorylation of the N-region and activation segment (Chong et al., 2001; Terai and Matsuda, 2005) . The N-region plays a critical role in Raf activation (Mason et al., 1999) . Negative charges within this region are required for activation and enhance the affinity of Raf-1 towards its substrate MEK (Xiang et al., 2002) . Raf-1 activation involves an inducible two-step mechanism leading to Ras-dependent phosphorylation of the N-region residues S338/339 and Y340/341 at the plasma membrane (Mason et al., 1999; Carey et al., 2003) . In contrast, the N-region of B-Raf is permanently negatively charged owing to the presence of the D448/449, which occupy positions equivalent to Y340/341 in Raf-1, and the constitutive phosphorylation of the S338 equivalent (S446) (Mason et al., 1999; Brummer et al., 2002) . The charged N-region of B-Raf is, at least in part, responsible for its high basal in vitro kinase activity, as mutation of the S446/S447/D448/ D449 sequence (referred to as SSDD sequence in the following) results in drastic reduction of both basal and Ras-GTP-stimulated in vitro kinase activities (Marais et al., 1997; Mason et al., 1999) . The importance of the SSDD sequence is partially explained by the crystal structure of the isolated B-Raf kinase domain in which D 448 was shown to stabilize the active conformation through a salt-bridge with R 506 of the aC-helix (Garnett and Marais, 2004; Wan et al., 2004) . These observations have led to a model in which the constitutive N-region charge primes B-Raf for full activation by Ras-GTPtriggered activation segment phosphorylation at the membrane (Brummer et al., 2002; Garnett and Marais, 2004; Morrison, 2004) . However, as the aforementioned crystal structure is based on a dephosphorylated protein, the importance of the serine residues within the Nregion is less understood. In striking contrast to Raf-1 S338 phosphorylation, phosphorylation of the evolutionary conserved S446 in B-Raf is neither stimulated by nor dependent on Ras-GTP/B-Raf interaction (Mason et al., 1999; Brummer et al., 2002) and is not affected by lipid raft disruption (Carey et al., 2003) . This suggests not only that S446 phosphorylation occurs prior to interaction with Ras-GTP but also that Raf-1 and B-Raf are phosphorylated in different subcellular locations and/or by distinct N-region kinases. Hence, these findings raise the possibility that the currently unidentified S446 kinase represents an isoform-specific Achilles heel for the inhibition of B-Raf. However, the importance of the N-region has not been addressed for full-length B-Raf in a biological system.
Another critical event in Raf activation is the Ras-GTP-triggered phosphorylation of the activation segment (T599 and S602 in human B-Raf; Zhang and Guan, 2000) . As N-region and activation segment phosphorylation act synergistically in Raf-1 activation (Chong et al., 2001) , it has been suggested that the constitutively charged N-region predisposes B-Raf for oncogenic hits (Davies et al., 2002; Morrison, 2004; Wellbrock et al., 2004a) . Indeed, gain-of-function mutations in the human BRAF gene have been identified in about 70% of malignant melanomas, 30% of papillary thyroid and serous ovarian carcinomas, 15% of colorectal cancers and to a lower frequency in a wide range of other tumours (Davies et al., 2002; Garnett and Marais, 2004) . The majority of these mutations (91%) lead to substitution of valine 600 by glutamic acid ) mimicking the conformational change of the activation segment induced by T599 and S602 phosphorylation (Garnett and Marais, 2004; Wan et al., 2004) . Tumours carrying a BRAF V600E allele Figure 1 The V600E mutation confers a high signalling potential to B-Raf regardless of its N-region charge or ability to interact with Ras-guanine 5 0 -triphosphate (GTP). (a) Domain structure of hemaggluttinine (HA)-tagged B-Raf (HA-B-Raf) proteins and location of the Ras/B-Raf interaction-regulating amino-acid residue R188, the N-region (S446/S447/D448/D449-sequence (SSDD-sequence)) and the activation segment (TVKS-sequence) and their corresponding mutants. Inhibiting and activating mutations are shown in blue and red, respectively. The two 14-3-3 binding motifs are also indicated. (b) Activation of extracellular signal regulated kinase (ERK) by B-Raf and its mutants. HEK293/ EBNA-2 cells were transfected with the indicated constructs. After 48 h, N-region phosphorylation was monitored using an antibody recognizing phosphorylated S446 (pS446). Hemaggluttinine (HA)-tagged B-Raf and endogenous B-Raf were detected with an anti-BRaf antibody. Active ERK-1,2 molecules were detected using an anti-phospho-ERK antibody. A representative experiment is shown.
Regulation of B-Raf signalling T Brummer et al display high MEK/ERK activity and the growth of their xenografts is highly dependent on this pathway . Expression of B-Raf V600E has been shown to transform fibroblasts and melanocytes as well as to induce haematopoietic dysplasia in mice and invasive melanomas in p53À/À zebrafish (Davies et al., 2002; Ikenoue et al., 2004; Wellbrock et al., 2004b; Mercer et al., 2005; Patton et al., 2005) . Likewise, suppression of BRAF V600E expression in melanoma lines abrogates their transformed phenotype (Hingorani et al., 2003; Karasarides et al., 2004) . However, little is known about the requirements of the B-Raf V600E oncoprotein to display biological activity. Nevertheless, this knowledge will be of particular importance for the development of selective B-Raf inhibitors. Indeed, the currently unidentified S446 kinase has been suggested to represent a potential therapeutic target in neoplasms with high B-Raf activity (Mercer and Pritchard, 2003) .
Given the important role of the N-region for the in vitro kinase activity of wild-type B-Raf (B-Raf wt ), we asked to what extent the charged N-region contributes to the biological activity of B-Raf wt and B-Raf
V600E
. To this end, we focused our analyses on the impact of B-Raf V600E and mutants thereof on several biological end points rather than by relying exclusively on their catalytic activity measured by immunocomplex in vitro kinase assays. This is of particular importance, as the high basal activity that is displayed by B-Raf in such assays does not necessarily reflect its in vivo potential to activate the ERK pathway or other biological end points (for a discussion, see MacNicol et al., 2000; Mercer and Pritchard, 2003) . Here, we show that the N-region is indeed important for the biological activity of B-Raf wt as it opposes negative regulatory constraints probably imposed by 14-3-3 binding to the CR2 domain. This necessity, however, is strongly reduced in B-Raf
. Furthermore, we show that the biological activity of B-Raf V600E is independent of its interaction with Ras-GTP.
Results

Comparison of B-Raf
wt and B-Raf V600E for their requirement for a negatively charged N-region and Ras-GTP binding to activate the ERK pathway In view of the high transforming activities of B-Raf V600E , we asked as to whether this oncoprotein still requires a negatively charged N-region or interaction with Ras-GTP. To this end, we introduced the V600E mutation into the pFlu/B-Raf vector encoding N-terminal, hemagglutinine (HA)-tagged chicken B-Raf wt , which is 93% identical with human B-Raf at the amino-acid level ( Figure 1a ; Brummer et al., 2003) . To investigate the effect of the V600E mutation on Ras-binding deficient B-Raf, we also introduced this mutation into a vector encoding Ras-GTP binding-deficient B-Raf
R188L
. In addition, expression vectors encoding either B-Raf or B-Raf V600E with S446/447 replaced by alanine residues were generated (B-Raf S446/7A ). Lastly, the entire SSDD sequence was mutated to alanine residues to express B-Raf proteins with a completely neutralized N-region ( Figure 1a ; B-Raf Nn , B-Raf Nn/V600E and B-Raf
). To test whether these B-Raf mutants could be efficiently expressed and were able to activate the ERK pathway, HEK293/EBNA-2 cells were transfected with the aforementioned vectors. The pFlu/B-Raf K483W vector encoding catalytically inactive B-Raf was also included in the study as a negative control. All B-Raf proteins were expressed at comparable levels ( Figure 1b ) and S446A mutants lacked anti-phospho-S446 reactivity as would be expected. Interestingly, B-Raf K483W was still detected by this antibody (Figure 1b , lane 10), demonstrating that S446 does not represent an autophosphorylation site. Longer exposure revealed that endogenous B-Raf was also phosphorylated at S446 (data not shown), which is in agreement with previous studies conducted in several cell types including HEK293 cells (Mason et al., 1999; Brummer et al., 2002; Tran et al., 2005) . Expression of B-Raf wt led to a low level of ERK phosphorylation, whereas B-Raf V600E provoked robust ERK activation as was reported for myc-tagged human B-Raf V600E in COS cells (Davies et al., 2002; Wan et al., 2004 displayed high ERK phosphorylation (Figure 1b ), indicating that, at least in this experimental system, the V600E mutation confers an enhanced signalling potential to B-Raf, regardless of the ability of B-Raf to interact with Ras-GTP or the presence of N-region charge.
Comparison of the biological activity of B-Raf wt and B-Raf The intensity of ERK phosphorylation was assessed by densitometry and normalized according to the loading control and the relative expression level of HA-tagged B-Raf proteins. The results of two independent experiments, one performed in HEK293/EBNA-2 cells (see Figure 1b) , resulted in the differentiation of 10-20% of transfectants (Figure 2 ). In line with its high signalling activity (Figure 1b) , approximately 50% of PC12 transfectants expressing B-Raf V600E displayed prominent neurites, a percentage that has been also observed upon expression of other Raf oncogenes (MacNicol et al., 2000; Dhillon et al., 2003) or the constitutively active enhanced green fluorescent protein (EGFP)-DB-Raf protein (Figure 2 ; Brummer et al. 2003) . In comparison with B-Raf wt transfectants, those expressing B-Raf R188L displayed a 3-4-fold reduction in neurite outgrowth, indicating that B-Raf must interact with Ras-GTPases to exhibit its full biological activity ( Figure 2b ). In contrast, PC12 transfectants expressing B-Raf R188L/V600E exhibited prominent neurites to the same extent as those expressing B-Raf V600E indicating that this oncoprotein does not require the interaction with Ras-GTP to induce PC12 differentiation.
Next, we investigated to what extent N-region charge contributes to the biological activity of B-Raf wt and B-Raf -and B-Raf Nn -expressing transfectants exhibited a very low degree of differentiation, comparable to that of BRaf K483W -expressing cells. This demonstrates for the first time the importance of a negatively charged N-region, and in particular of the phosphorylation sites S446/447, for the biological activity of full-length B-Raf. However, the necessity for a negatively charged N-region is rendered obsolete in a B-Raf V600E background as indicated by the biological activity of the corresponding S446/7A and Nn mutants. Furthermore, even the triple B-Raf R188L/Nn/V600E mutant displayed a high differentiative activity (Figure 2b ), which also provoked a prominent ERK activity in HEK293 cells (data not shown). It should be also emphasized that at least 700 HA-positive cells (regardless of their staining intensity) were analysed in this assay. Consequently, the obtained result is not weighted on certain B-Raf transgene expression levels. Thus, in the PC12 assay, the V600E gain-of-function mutation dominates over mutations within the SSDD sequence and RBD that compromise the activity of the wild-type protein.
The influence of 14-3-3 binding on the biological activity of B-Raf wt and B-Raf
V600E
Next, we asked why N-region phosphorylation is indispensable for the biological activity of B-Raf wt . Recently, it has been suggested that negative charges in the N-region are involved in the maintenance of a more 
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open conformation of B-Raf that facilitates the access of activation segment kinases that phosphorylate T599 and S602 (Mercer and Pritchard, 2003) . Similarly, Wan et al. (2004) have suggested that phospho-S446 may relieve constraints imposed by the N-terminus. Considering these models, we reasoned that the S365A mutation, which should prevent binding of 14-3-3 to the CR2, would rescue the impaired biological activity of BRaf S446/7A . As binding of 14-3-3 proteins to the CR2 has been only confirmed for Raf-1, but not for B-Raf, we first determined whether S365 is indeed involved in 14-3-3 binding. As S729 of B-Raf is a known 14-3-3 recruitment site (MacNicol et al., 2000) , we performed alanine substitutions of S365 and S729, singly and in combination. Many 14-3-3 client proteins possess more than one 14-3-3 binding site and in this case, it is necessary to eliminate both binding sites to observe an altered stoichiometry of the 14-3-3/client protein complex (Yaffe, 2002) . Indeed, mutation of both sites was required to achieve a drastic reduction of the B-Raf/ 14-3-3 interaction ( Figure 3a ). Therefore, both S365 and S729 contribute to binding and, at least under these experimental conditions, the third potential 14-3-3 binding site within the cysteine-rich domain of CR1 (Hekman et al., 2004) appears not to be a major mediator of 14-3-3/B-Raf interaction.
We then investigated whether the S365A mutation alters the biological activity of B-Raf proteins with or without a neutralized N-region. In the PC12 assay, the S365A mutation markedly enhanced the biological activity of B-Raf (Figure 3b ), indicating for the first time that S365 kinases, for example, Akt or SGK (Zhang et al., 2001) , serve as potent negative regulators of B-Raf in a biological system. However, the differentiative potential of HA-B-Raf S365A did not reach that of B-Raf V600E (Figure 3b ), indicating that biological readouts such as 'cellular' MEK/ERK phosphorylation (Figure 3c/d) and PC12 differentiation are appropriate tools to evaluate the activities of B-Raf proteins. It should be also noted that the S365A mutation did not further increase the high biological activity of B-Raf V600E in the PC12 assay (data not shown). Importantly, the presence of the S365A mutation in B-Raf S446/7A rescued the detrimental effect of the S446/447A mutation in the PC12 cell assay (Figure 3b) . Furthermore, in a preliminary experiment, the S365A mutation also rescued the impaired biological activity of B- : 51.3% (percentages indicate differentiated cells obtained in this experiment; n ¼ 300 hemeaggluttinine-positive transfectants). The S365A mutation also elevated the MEK/ERK activation potential of B-Raf, but not as dramatically as V600E and this effect was progressively reduced when S365A was combined with S446/7A or a completely neutralized N-region (Figure 3c) . MacNicol et al. (2000) have demonstrated that the S729A mutation blocks the high biological activity of the isolated B-Raf CR3 while having only a moderate impact on its in vitro kinase activity. In agreement with this, we show that the enhanced cellular MEK kinase activity of B-Raf S365A was abolished upon introduction of the S729A mutation, demonstrating that this C-terminal 14-3-3 binding site is essential for the coupling of B-Raf to downstream effectors ( Figure 3d ). Taken together, these data suggest that one function of the negatively charged N-region is to oppose the stabilization of a closed B-Raf conformation by 14-3-3 binding to phospho-S365. Interestingly, these results also highlight another isoform-specific difference between B-Raf and Raf-1 as Light et al. (2002) have shown that the S259A mutation does not rescue the impaired kinase activity of Raf-1
S338A
.
Determination of the in vitro kinase activity of B-Raf mutants Next, we determined the in vitro kinase activities of the aforementioned B-Raf mutants. To this end, we used a coupled in vitro kinase cascade assay system (Alessi et al., 1995) , in which immunopurified HA-B-Raf phosphorylates GST-MEK that in turn activates GST-ERK2. The activation of GST-ERK2 is then assayed using myelin basic protein (MBP) as a substrate in the presence of radioactive ATP. During these experiments, however, we experienced a high background phosphorylation of MBP (data not shown). In contrast, we found that the measurement of phosphorylated GST-MEK1 using a phospho-specific antibody recognizing the amino-acid residues S217 and S221, which are specifically phosphorylated by Raf, provided a more dynamic range. In order to compare the in vitro kinase assay results with the pMEK/pERK data from our previous assays (Figures 1b and 3c/d), we immunoprecipitated the various B-Raf proteins from Phoenix-eco cells grown in the presence of serum. Despite its crippled biological activity in PC12 ( Figure 2 ) and Raf-deficient DT40 B cells (Brummer et al., 2002) , the B-Raf R188L mutant displayed an in vitro kinase activity comparable to B-Raf wt , in agreement with the observations of Marais et al. (1997) . Similar to Mason et al. (1999) , we also observed a reduction of the activity of B-Raf wt proteins with a partial or neutralized N-region in some experiments, although this result could not be reproduced in all experiments as indicated by the comprehensive analysis in Figure 4a . As reported previously, B-Raf V600E displayed a robust MEK kinase activity, which was about 10-fold higher than that of B-Raf wt , a differential that has also been observed by other laboratories (Davies et al., 2002; Ikenoue et al., 2003 Ikenoue et al., , 2004 Grbovic et al., 2006) . As expected from the aforementioned experiments in HEK293 and PC12 cells, this high activity was not considerably influenced by the R188L or S446/7A mutations. Interestingly, however, the B-Raf Nn/V600E mutant displayed a 2.5-fold reduction in activity, indicating that the D448/449 residues contribute to the high in vitro kinase activity of B-Raf V600E proteins (Figure 4) , a difference that was not detected using PC12 cell differentiation and cellular ERK phosphorylation as read-outs. Furthermore, the in vitro kinase activity of B-Raf S365A was comparable to that of B-Raf V600E and about twofold more active than the B-Raf Nn/V600E mutant (Figure 4) , although both , which they attributed to their use of a more physiological ATP concentration of 5 mM. This contrasts with the ATP concentration of 100-800 mM used for the assays in Figure 4a and the aforementioned publications. Therefore, we have repeated the in vitro kinase assay with B-Raf wt and the key mutants B-Raf V600E , B-Raf Nn/V600E and B-Raf S365A at 5 mM ATP. This increased ATP concentration had no significant effect on the differential between B-Raf wt and the B-Raf mutants in question (Figure 4b) , showing that, under our experimental conditions, the ATP concentration of 130 mM does not limit the activity of B-Raf V600E . Furthermore, using different amounts of activated B-Raf (D1-415), we could demonstrate that 1 ng of this protein, which was used as positive control in Figure 4a /b and displays a comparable activity to B-Raf V600E , does not saturate the kinase assay (Figure 4c) . A possible explanation for the contrasting differential between B-Raf wt and B-Raf V600E in our study and that of Wan et al. (2004) is that we used RIPA buffer for our immunoprecipitations, whereas the latter utilized more mild conditions (0.5% NP-40). Whereas our conditions are probably more specific for B-Raf (by reducing the risk of contamination with other MEK kinases such as Raf-1 ), they may lead to the dissociation of important cofactors such as the HSP90/p50cdc37 complex (Grammatikakis et al., 1999; Grbovic et al., 2006) . N-region charge and Ras-GTP binding are dispensable for the transforming potential of B-Raf
V600E
We next analysed the potential of B-Raf V600E proteins with a neutralized N-region or a defective RBD to induce oncogenic transformation. To this end, we infected low passage MCF-10A cells with ecotropic retroviruses encoding the indicated B-Raf protein and green fluorescent protein (GFP) (as infection marker) from a bicistronic transcript. MCF-10A cells are immortalized but non-transformed human mammary epithelial cells that form a regular, cobblestone-like monolayer indicating an intact contact inhibition response. As shown in Figure 5 , MCF-10A cells expressing only GFP (vector) or the non-V600E B-Raf proteins displayed the typical epithelial phenotype and were well integrated into the growth-arrested monolayer. In contrast, oncogenic Ha-RasG12V (positive control for transformation) and B-Raf V600E -expressing cells exhibited classical features of a transformed phenotype as they lost contact inhibition and grew out (or its N-region or RBD mutants) in murine NIH 3T3 cells also resulted in a transformed phenotype as indicated by the appearance of refractile cells devoid of any contact inhibition response (data not shown). Thus, the transforming potential of B-Raf V600E is not affected by mutations neutralizing N-region charge or preventing the interaction with Ras-GTP.
Expression of B-Raf
V600E induces epithelial-mesenchymal transition in MCF-10A cells Given the aforementioned findings and the involvement of BRAF mutations in particular cancers of epithelial origin, we were interested in the ability of B-Raf V600E and mutants thereof to influence the epithelial morphogenesis programme of MCF-10A cells. First, we analysed whether B-Raf V600E affects the morphology of MCF-10A cells maintained at low density. Non-infected or empty vector-infected MCF-10A cells grew as clusters of cells in close contact and with strong cell-substratum adhesion (Figure 6a) (Figure 6a ).
When grown in three-dimensional (3D) matrigel cultures, MCF-10A cells undergo a series of proliferative and morphogenetic events leading to the formation of growth-arrested acini-like spheroids composed of a single layer of polarized epithelial cells surrounding a hollow lumen (Debnath et al., 2002; Brummer et al., 2006) . We were therefore interested in analysing the effect of B-Raf and its mutants on this morphogenetic process. MCF-10A cells expressing B-Raf wt and corresponding non-V600E mutants including active B-Raf-S365A formed regular acini at day 10 ( Figure 6b) . In marked contrast, colonies expressing B-Raf V600E or any of its mutants formed 'grape-like' colonies of individual, dis-cohesive cells growing in loose contact that displayed a strong reduction in total b-Catenin staining (Figure 6b) , most likely as a result of the loss of membraneous E-Cadherin (Figure 6c ). Our bi-cistronic approach and the fact that we used an unsorted pool of MCF-10A cells with varying GFP expression levels for the 3D matrigel culture assays also allowed us to correlate the degree of b-Catenin reduction in individual cells/colonies with the GFP (B-Raf) expression level. This analysis revealed that all GFP-positive cells/ colonies expressing B-Raf V600E oncoproteins displayed an aberrant morphology and a strong reduction in b-Catenin staining, demonstrating that these phenotypic changes are not confined to cells with high expression levels of B-Raf V600E or B-Raf Nn/V600E
, but can be observed at low expression levels as well (Figure 7) .
The findings from the matrigel cultures and the morphology observed in monolayer culture suggested that MCF-10A cells expressing B-Raf V600E proteins undergo epithelial-mesenchymal transition (EMT). In order to investigate this further, we subjected RIPAbuffer lysates of the MCF-10A pools to Western Blot analysis using antibodies for E-Cadherin (epithelial (Figure 8) . Furthermore, expression of B-Raf V600E proteins led to a reduction in b-Catenin expression, most likely owing to the loss of its membranous anchorage. As in our previous assays, the S446/7A, Nn-and R188L mutations that attenuate the biological activity of B-Raf wt failed to halt EMT induced by the V600E mutants ( Figures 6, 7 and 8a) . Also, as observed in HEK293/EBNA-2 transfectants (Figure 1b) , expression of all V600E mutants induced a comparable and robust ERK activation. In light of our finding that the S729A mutation blunts the cellular MEK/ERK activation potential introduced by the S365A mutation (Figure 3d ), we were surprised to see that the B-Raf V600E/S729A mutant still provokes a prominent ERK activation and EMT (Figure 8b ).
Discussion
In this study, we have investigated the requirements for N-region charge, 14-3-3 binding and recruitment to Ras-GTP in the activation and biological activity of B-Raf and its oncogenic counterpart B-Raf V600E . Our findings reveal marked differences in the requirements of these two proteins to achieve their full signalling potential, shed light on the oncogenic potential of B-Raf and provide important information regarding the validity of potential therapeutic approaches directed against B-Raf V600E . V600E expression is correlated with loss of plasma membrane-bound E-cadherin. The experiment was set-up as in (b). Colonies were stained with anti-E-Cadherin (Cy-3; red) and TOPRO-3 (blue) as a DNA counter-stain.
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T Brummer et al B-Raf proteins with a partially or completely neutralized N-region display a lower signalling potential and are impaired in their ability to induce PC12 differentiation, demonstrating for the first time an important role for the negatively charged N-region in the biological activity of full-length B-Raf wt (Figures 1  and 2) . However, what is the role of the N-region in the activation of B-Raf wt ? According to our current model, B-Raf is primed for activation by constitutive S446 phosphorylation prior to the interaction with Ras-GTP (Brummer et al., 2002) . The phosphorylation of S446 (and perhaps S447) leads to a maximal negatively charged N-region, which induces a conformational change rendering the activation segment more accessible to its cognate kinase. Our finding that the S365A mutation increases not only the biological activity of B-Raf wt but also rescues that of B-Raf with a neutralized N-region (Figure 3b and c) strongly supports a model in which a major function of the N-region is to oppose the transition into an inactive conformation stabilized by binding of a 14-3-3 dimer to S365 and S729. Our model (Figure 9a ), similar to that suggested by Mercer and Pritchard (2003) , is consistent with recent studies showing that the negatively charged N-region of Raf-1 relieves autoinhibition by the N-terminal moiety owing to its reduced affinity towards a CR3 with a charged N-region (Cutler et al., 1998; Tran and Frost, 2003) . However, we accept that similar experiments led to the alternative conclusion that the charged N-region induces a conformational change that does not affect the interaction between N-and C-terminal moiety but renders the CR3 resistant to the autoinhibition imposed by the N-terminal moiety (Chong and Guan, 2003) . Furthermore, while our manuscript was in preparation, Tran et al. (2005) reported that introduction of the Regulation of B-Raf signalling T Brummer et al S446A mutation into the isolated CR3 increased the affinity of this region towards the isolated N-terminal domain of B-Raf (Tran et al., 2005) . Therefore, these and our data provide strong evidence for a model wherein an important function of phospho-S446 is to relieve the autoinhibition imposed by the N-terminal region of B-Raf. In this regard, the charged N-region may recruit proteins that stabilize this 'primed' conformation. Such proteins might also protect the Nregion against phosphatases and could provide an explanation for the constitutive S446 phosphorylation of B-Raf that is observed in different cell types and species. Indeed, recent findings have shown that the adapter protein CNK1 binds to Raf-1 in an inducible and Ras-GTP-dependent manner, whereas its association with B-Raf and pre-activated Raf-1 mutants with increased N-region charge is constitutive and Ras-GTP independent (Ziogas et al., 2005) . Thus, proteins like CNK1 may assist in the stabilization of the primed state. The charged N-region is also likely to stabilize the active conformation of the kinase domain through a saltbridge between D 448 and R 506 (Wan et al., 2004) . This second important function is likely to explain the different in vitro kinase activities between S446/7A and Nn mutants (Figure 4a/b) . Thus, the SSDD motif might serve a double function in B-Raf activation, one to facilitate full activation by membrane-resident activation segment kinases by maintaining a primed conformation and another to stabilize the active conformation of the kinase domain after the activation segment has been phosphorylated.
In the case of B-Raf
V600E
, introduction of the S446/7A mutations did not affect kinase activity in vitro, whereas replacement of the entire SSDD sequence by alanine residues diminished this approximately 2.5-fold, although the activity of the B-Raf Nn/V600E mutant was still four times higher than that of B-Raf wt (Figure 4) . However, the B-Raf Nn/V600E mutant displayed comparable biological activity in HEK293 (ERK phosphorylation), PC12 (differentiation) and MCF-10A cells (ERK phosphorylation, transformation and EMT induction) as B-Raf V600E (Figures 1, 5-8) . Similarly, while our . This leads to a maximally negatively charged N-region, which confers an open activation-competent conformation to B-Raf by opposing the closed conformation mediated by simultaneous binding of a 14-3-3 dimer to phosphorylated S365 and S729. Presumably, this open conformation of B-Raf that is achieved prior to interaction with Ras-GTP also explains why it binds MEK-1 with higher affinity than Raf-1 (Papin et al., 1998) . Induction of Ras-GTP by extracellular signals results in the recruitment of pre-activated B-Raf to the plasma membrane where it is fully activated by activation segment kinases. This assumption is supported by the observation that a membrane-targeted B-Raf-CAAX protein displays constitutive MAPKKK and high transforming activities (Papin et al., 1998; Carey et al., 2003) . Phosphorylation of the activation segment destabilizes the inactive conformation of the kinase domain (Wan et al., 2004) and renders B-Raf fully active. (b) Situation of B-Raf with a neutralized N-region. If the N-region is neutralized, most B-Raf molecules will reside in a closed, inactive conformation stabilized by 14-3-3 proteins binding to S365 and S729. Only upon Ras-GTP binding is the 14-3-3 dimer displaced from S365, switching B-Raf into a more open conformation permitting phosphorylation and the conformational change of the activation segment. If this last step is mimicked by the V600E mutation, the preceding steps of S446 phosphorylation and interaction with Ras-GTP are superfluous (c, d).
Regulation of B-Raf signalling
T Brummer et al manuscript was under revision, Emuss et al. (2005) reported that B-Raf Nn/V600E displayed a strong reduction in its in vitro kinase activity but retained a very high transforming activity and induced MEK phosphorylation to a comparable extent as B-Raf V600E . As our study and that of Emuss et al. (2005) both involve ectopic expression of the respective proteins, it could be argued that our inability to detect a difference in the biological activity of B-Raf V600E proteins with and without complete N-region charge neutralization could be owing to their levels of expression. Alternatively, the difference between the in vitro kinase activities of B-Raf V600E and B-Raf Nn/V600E might represent an artefact of the enzymatic conditions in vitro and may not apply to these BRaf V600E proteins in their native environment where membrane phospholipids and other co-factors are present. Formal resolution of this issue will require germline knock-ins of the V600E mutation, in the presence and absence of the Nn mutations, into the murine B-raf locus. Furthermore, our finding that BRaf S365A displays an in vitro kinase activity comparable to B-Raf V600E , but exhibits a reduced ability to activate ERK (Figure 3 ), induce PC12 cell differentiation ( Figure 3 ) and to promote EMT in MCF-10A cells (Figures 6 and 8) , indicates that our in vivo assays are capable of discriminating between the biological activities of activated B-Raf proteins. We assume that the contrasting relative activities of B-Raf V600E and BRaf S365A in vitro and in vivo reflect the differential sensitivity of these proteins to endogenous negative regulatory factors, for example, RKIP or Sprouty proteins, (Tsavachidou et al., 2004; Kolch, 2005) , which may be lost during the immunopurification procedure, or the capacity of B-Raf V600E to trigger additional signalling pathways, a property not reflected in the in vitro kinase assay employed.
However, if N-region charge opposes a closed, inactive conformation of B-Raf, why are the biological and, to a lesser extent, in vitro kinase activities of B-Raf V600E resilient to N-region neutralization? Among several possibilities, we think that this question can be best explained by the model of sequential B-Raf activation (Figure 9 ). According to the recently published crystal structure, phosphorylation of T599/S602 or the V600E mutation distorts the activation segment in such a way that the inactive conformation that is stabilized by the hydrophobic interaction between V600 in the activation segment and F467 in the glycine-rich loop is disrupted (Hubbard, 2004; Wan et al., 2004) . If all the priming steps preceding B-Raf wt activation are only required to allow activation segment phosphorylation and a switch of the kinase domain to an active conformation (Figure 8a ), these events become superfluous if this final step is mimicked by the V600E activation (Figure 8c/d) . Alternatively, as suggested by Wan et al. (2004) , the glutamic acid residue introduced by the V600E mutation might contact K507 within the Ca-helix and thereby stabilize the active conformation. As the salt-bridge between D448 (and maybe phospho-S446/7) and R506 is also implicated in this process (Garnett and Marais, 2004) , the E600/K507 salt-bridge could substitute for the absent N-region/R506 interaction in B-Raf V600E proteins with a neutralized N-region. In order to test this hypothesis, it would be interesting to analyse the requirement of the activated B-Raf V600G/K/M/R mutants (Wan et al., 2004) for a charged N-region, as these mutants cannot generate the aforementioned E600/K507 salt-bridge. However, a different explanation must underlie the relatively high in vitro kinase activity of the B-Raf S365A/Nn mutant, which is comparable to that of B-Raf Nn/V600E (Figure 4) , as the alternative saltbridge cannot be formed in this protein.
In the present study, we are the first to directly analyse the requirements of B-Raf V600E for Ras-GTP by using the Ras-GTP-binding deficient B-Raf R188L mutant, which is refractory to extracellular signals (Brummer et al., 2002) and cannot be recruited to the plasma membrane by Ras (Marais et al., 1997) . Our analysis of the HA-B-Raf R188L/ V600E mutant clearly demonstrates that the biological activity and transforming potential of B-Raf V600E are independent of its ability to interact with Ras-GTP and imply that the V600E mutation circumvents the need for Ras-GTP-stimulated phosphorylation of T599 and S602. Consequently, this finding would also explain why BRAF V600E and oncogenic RAS alleles are mutually exclusive in cancer types characterized by a high incidence of RAS mutations. However, our data do not exclude the possibility that B-Raf V600E induces autocrine loops signalling through Ras-GTPases and such a scenario would also explain why B-Raf V600E requires the presence of isoprenylcysteine-carboylmethyltransferase, an enzyme required for the correct subcellular localization of Ras-GTPases, for full transformation (Bergo et al., 2004) .
In the present study, we also show for the first time that expression of B-Raf V600E induces EMT of MCF-10A cells. The observed reduction in E-Cadherin expression is presumably owing to chronic ERK activation (Figure 8 ), which would lead to decreased transcription of the E-Cadherin encoding CDH1 gene via the upregulation of Snail family repressors (Thiery, 2002) . Furthermore, loss of E-Cadherin expression was correlated with a strong reduction in b-Catenin expression, presumably, owing to loss of membranous anchorage. The resulting subcellular redistribution of b-Catenin might then increase nuclear b-Catenin signalling, a hypothesis supported by the strong upregulation of the mesenchymal marker and b-Catenin target gene vimentin (Gilles et al., 2003) . Our findings are of particular interest as aberrant b-Catenin signalling and EMT have been implicated as important processes in the metastatic progression of tumours with a high incidence of BRAF V600E mutations such as melanomas, thyroid and colorectal carcinomas (Thiery, 2002) . Likewise, as EMT and its opposite process are crucial and tightly regulated events during metazoan development, our finding that B-Raf V600E induces EMT might help to explain the embryonic lethal phenotype of mouse embryos with an induced B-raf V600E allele (Mercer et al., 2005) . In summary, five fundamental regulatory differences between B-Raf wt and B-Raf V600E have now been identified, as the V600E mutation circumvents the require-ment for Ras-GTP binding, N-region charge and binding of 14-3-3 to S729 (Figures 1, 2 , 5, 6, 7 and 8), and confers resistance to negative feedback regulation by Sprouty proteins (Tsavachidou et al., 2004) and the effects of S579A mutation (Zhu et al., 2005) . Our data suggest that the high biological activity of B-Raf V600E cannot be directly inhibited by compounds interfering with Ras activation or S446 phosphorylation and that the development of therapies for tumours harbouring a BRAF V600E allele should focus on the inhibition of the catalytic centre or expression of B-Raf. However, still to be developed S446 kinase inhibitors might be useful for the treatment of pathologies that are dependent on B-Raf signals but contain BRAF wt alleles, for example, tumours overexpressing B-Raf wt or harbouring activating mutations of upstream activators such as Ras or receptor tyrosine kinases, or polycystic kidney disease, which is characterized by increased B-Raf activation (Tanami et al., 2004; Yamaguchi et al., 2004) . Similarly, S446 kinase inhibitors might be useful to attenuate the activity of other clinically relevant non-V600E B-Raf mutants. Indeed, recent work by Emuss et al. (2005) suggests that this concept might apply to the B-Raf E586K mutant. Thus, unlike many other BRAF mutations, the V600E mutation event might be subject to an extraordinary positive selection, because the resulting oncoprotein appears to be particularly independent of key positive regulatory events required for B-Raf wt activation, while also conferring resistance to negative modulation. Thus, our findings also contribute to a better understanding of why this mutation is so frequently found in human tumours.
Materials and methods
Plasmid constructs
The pFlu/B-Raf vector encoding HA-tagged bursal chicken BRaf has been described (Brummer et al., 2003) . It should be noted that the recently revised human B-Raf cDNA (Wellbrock et al., 2004a) as well as the chicken B-Raf cDNA used in this study (Brummer et al., 2003) represent the same splice variant (lacking the neuron-specific exon 10) and are both one amino acid longer than the previously reported human cDNA. Consequently, amino-acid (aa) residues like R187, S364, S445, V599 and S728, which were mentioned throughout earlier publications, correspond in fact to R188, S365, S446, V600 and S729 in both chicken B-Raf and the recently revised human B-Raf (for a review, see Wellbrock et al. (2004a) ). For the construction of the retroviral vectors, the cDNA was subcloned into the pMIG vector (a kind gift of Dr Warren S Pear) to yield pMIG/B-Raf expressing a bi-cistronic transcript encoding HA-tagged B-Raf and EGFP as an infection marker. Similarly, the Ha-Ras G12V cDNA was subcloned from pCMV5/ Ha-Ras G12V (a kind gift of Dr Peter E Shaw) into pMIG. All mutations were introduced using the 'Quick change' sitedirected mutagenesis kit (Stratagene).
Transfections, retroviral infections, differentiation and transformation assays HEK293/EBNA-2 cells (Invitrogen, Paisley, UK) and Phoenix-eco, a HEK293 derivative, and PC12 cells were grown as described (Brummer et al., 2003 (Brummer et al., , 2006 /35 mm diameter dish) were transfected with 3 mg plasmid DNA using 10 ml Gene Juice reagent (Novagen, Schwalbach, Germany) in 3 ml culture medium according to the protocol supplied by the manufacturer. After 3-4 days, PC12 transfectants were identified by positive HA staining and neuronal differentiation was quantified by scoring cells with neurites longer than the size of two cell bodies as described previously (Brummer et al., 2003) . Phoenix-eco cells were transfected with 10 mg plasmid DNA using Polyfect (Qiagen, Hilden, Germany).
MCF-10A cells expressing the receptor for murine retroviruses (MCF-10A/ecoR; a kind gift of Drs Danielle K Lynch and Joan Brugge) were grown and infected with retroviruses as described (Brummer et al., 2006) . For biochemical experiments, EGFP-positive cells were sorted by flow cytometry to homogeneity and cultured as pure population. As MCF-10A cells expressing HA-B-Raf V600E (or any mutation thereof) display strongly reduced cell-cell and cell-substrate adhesion, cells infected with pMIG/B-Raf V600E (or any mutation thereof) were isolated by flushing infected cell lawns with growth medium and re-plating of the cells in the supernatant. This method yielded populations highly enriched for EGFPpositive cells. Three-dimensional basement matrigel cultures were set up, maintained, fixed and stained with the indicated antibodies as described (Brummer et al., 2006) .
Antibodies The anti-phospho-Raf-1 S338 antibody recognizing pS446 was purchased from Upstate Biotechnology, Charlottesville, VA, USA. B-Raf proteins were detected using anti-B-Raf F7 antibody (Santa Cruz, CA, USA). Other antibodies used in this study were anti-E-Cadherin (clone 36) and b-Catenin (clone 14) (both BD Transduction Laboratories, Heidelberg, Germany), anti-Vimentin (Amersham, Castle Hill, NSW, Australia), anti-14-3-3b (recognizes all 14-3-3 isoforms; Santa Cruz), anti-HA antibodies 12CA5 or 3F10 (Roche Molecular Bioscience, Castle Hill, NSW, Australia), anti-ERK2 (Transduction labs) and anti-p42/p44 MAPK (Cell Signaling Technology, Beverly, MA, USA). Phospho-ERK was detected using antiactivated MAPK 12D4 (nanotools) or phospho-MAPK (Cell Signaling Technology, Beverly, MA, USA).
Western blot analysis TCLs were generated and analysed by Western Blotting as described previously (Brummer et al., 2004) . If not stated otherwise, cells were lysed in RIPA-buffer (50 mM HEPES, pH 7.4; 1% Triton X-100; 0.5% Sodium deoxycholate, 0.1% SDS, 50 mM Sodium fluoride, 5 mM EDTA, supplemented with protease inhibitors (0.1 mg/ml aprotinin, 0.5 mg/ml leupeptin, 1 mM AEBSF or PMSF). Transfectants were directly processed to TCLs without starvation.
In vitro kinase assays A B-Raf in vitro kinase assay kit (Upstate Biotechnology) was used for the determination of the in vitro kinase activities of the various B-Raf proteins. A subconfluent 10 cm dish of Phoenix-eco cells was transfected with 10 mg of the indicated pMIG plasmids as described above and was lysed in 1.5 ml RIPA buffer 48 h post transfection. Subsequently, 0.5-1 mg rat anti-HA antibody 3F10 was added to 1.2 ml cleared TCL for 2 h and then incubated with 50 ml Protein G-Sepharose slurry for 3 h. Following three washes with 1 ml RIPA-buffer and four washes with 1 ml Kinase assay buffer (KAB; 20 mM 4-Morpholinepropanesulfonic acid (MOPS), pH 7.2; 25 mM b-glycerol phosphate; 5 mM EGTA, 1 mM sodium orthovanadate, 1 mM dithiothreitol), the beads were resuspended in 100 ml KAB. Then, 10 ml of this suspension were mixed with 0.4 mg GST-MEK1, 1 mg GST-ERK2 and supplied 10 ml Mg 2 þ /ATP solution (75 mM MgCl 2 ; 500 mM ATP dissolved in KAB) and KAB added to a final volume of 38 ml. For the in vitro kinase assays with a final ATP concentration of 5 mM, the supplied Mg 2 þ /ATP solution was replaced by 10 ml of self-made Mg 2 þ /ATP solution (75 mM MgCl 2 ; 20 mM ATP). The reaction was incubated at 301C for 30 min and immediately stopped by addition of sample buffer and boiling for 5 min. Subsequently, the reactions were diluted 1:4, separated by SDS-PAGE and blotted with phospho-MEK antibodies as read-out for the MEK kinase activity of the purified HA-B-Raf proteins. The phospho-MEK signal was analysed using IP Lab Gel software (Signal Analytics Corp.). Following subtraction of the background signal (kinase assay reaction performed with anti-HA immunoprecipitates of empty vector-transfected cells), the relative, specific B-Raf activity was determined by division of each activity by that of B-Raf wt . As a positive control, 1 ng of an activated human B-Raf protein (Upstate Biotechnologies) with an N-terminal truncation of amino acids 1-415, which was purified from SF9 cells, was used in a parallel assay as directed by the manufacturer.
Glutathionine-S-transferase fusion protein pulldown assay Escherichia coli BL21Lys were transformed with either pGEX-4T (for production of GST, Pharmacia) or pGEX-14-3-3b (a kind gift from Dr John Hancock; (Roy et al., 1998) ) plasmids. Expression and purification of GST proteins was performed as described previously (Brummer et al., 2004) . Phoenix cells expressing HA-tagged B-Raf proteins (confluent 10 cm dish) were lysed in ice-cold lysis buffer (1% v/v Triton-X-100, 50 mM HEPES pH 7.5, 150 mM NaCl, 10% v/v glycerol, 1.5 mM MgCl 2 , 1 mM EGTA, 10 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulphonyl fluoride, 10 mg/ml aprotinin and 10 mg/ml leupeptin). Postnuclear supernatants were incubated overnight with an appropriate volume of GST-fusion proteins (approx. 25 mg) immobilized on glutathionine-Sepharose beads. Subsequently, the beads were washed six times with 1 ml lysis buffer, resuspended in 100 ml lysis buffer, mixed with 50 ml 3 Â sample buffer and denatured by boiling for 5 min. The samples were then analysed by Western blotting.
